Tris Pharma, Inc.
Clinical trials sponsored by Tris Pharma, Inc., explained in plain language.
-
New Once-Daily painkiller could reduce opioid use after surgery
Symptom relief CompletedThis completed Phase 3 trial tested a new drug called cebranopadol (TRN-228) for moderate to severe acute pain after bunionectomy. 240 participants received either cebranopadol once daily, oxycodone four times daily, or placebo for three days. The study measured pain relief and w…
Phase: PHASE3 • Sponsor: Tris Pharma, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 08:14 UTC
-
New Once-Daily pill could ease Post-Surgery pain
Symptom relief CompletedThis study tested a new drug called cebranopadol for treating moderate to severe pain after a tummy tuck (abdominoplasty). 279 adults took either a low or high dose of the drug or a placebo once daily for two days. Researchers measured pain levels over time and how much extra pai…
Phase: PHASE3 • Sponsor: Tris Pharma, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 08:13 UTC
-
New Opioid-Like drug put to the test: will it be less addictive?
Knowledge-focused CompletedThis study tested a new painkiller called cebranopadol, given as a nasal spray, to see how much recreational opioid users liked it compared to oxycodone and a placebo. 48 healthy volunteers who had used opioids for fun in the past took part. The goal was to measure the drug's abu…
Phase: PHASE1 • Sponsor: Tris Pharma, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:05 UTC